## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims:

1-38. (Canceled).

- 39. (Withdrawn) A method for promoting angiogenesis in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.
- 40. (Withdrawn) A method for treating a disease or condition characterized by the absence of desired angiogenesis in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.
- 41. (Withdrawn) The method according to claim 40, wherein the disease or condition is selected from the group consisting of: coronary artery disease, wound healing, peripheral vascular disease associated with diabetes, peripheral vascular disease, peripheral artery disease.
- 42. (Currently Amended) A method for treating or preventing a condition or disease characterized by pathological vascular remodeling in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B,

wherein said biological activity is selected from the group consisting of promoting endothelial cell adhesion, spreading and migration.

43. (Currently Amended) The method according to claim 42, wherein the disease or

condition is selected from the group consisting of: hypertension, <u>restenosis</u> restinosis, transplant vasculopathy, arteriosclerosis, ischemia, pulmonary hypertension, asthma, myocardial infarction and cerebrovascular infarction.

44. (Withdrawn) A method for promoting vascular quiescence in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

45. (Withdrawn) The method according to claim 44, wherein the subject suffers from a condition selected from the group consisting of: asthma, hypertension, pulmonary hypertension.

46-48. (Canceled).

49. (Withdrawn) A method for reducing neointima formation in a blood vessel in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

50. (Withdrawn) A method for inhibiting vascular injury-induced vascular narrowing or occlusion in a subject comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

- 51. (Withdrawn) A method for preventing vascular injury induced ischemia comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.
- 52. (Withdrawn) A method for promoting endothelial cell adhesion, spreading and migration comprising the step of contacting the cell with Nogo-B or a fragment thereof that retains a biological activity of Nogo-B.

Appln. No. 10/554,252 Response dated March 9, 2009 In Response to the Office Action dated October 8, 2008

53. (Withdrawn) A method for inhibiting vascular smooth muscle cell migration comprising contacting the cells with Nogo-B or a fragment thereof that retains a biological activity of Nogo-B.

54. (Withdrawn) A method for treating a subject suffering from a vascular injury comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

55. (New) The method according to claim 42, wherein the disease or condition is ischemia.

56. (New) A method for treating a condition or disease characterized by pathological vascular remodeling in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B comprising amino acids 1-200 of the N-terminus of Nogo-B that retains a biological activity of Nogo-B, wherein said biological activity is selected from the group consisting of promoting endothelial cell adhesion, spreading and migration.

57. (New) The method according to claim 56, wherein the disease or condition is selected from the group consisting of: hypertension, restenosis, transplant vasculopathy, arteriosclerosis, ischemia, pulmonary hypertension, asthma, myocardial infarction and cerebrovascular infarction.

58. (New) The method according to claim 56, wherein the disease or condition is ischemia.

59. (New) The method according to claim 56, wherein the pathological vascular remodeling is in response to an injury.